May 14, 2013

$PVCT CEO Letter: Final MM P2 PV-10 data presented, Systemic immune response shown in multiple cancers

The takeaways appear to be:
  • Final MM Phase 2 data finally was reported in 2012,
  • Murine study data, via Moffitt, showed PV-10's systemic, anti-tumor immune response,
  • This systemic immune response was shown in multiple cancers (i.e., melanoma, lung, breast),
  • Combination therapy complementariness of PV-10 and "ipi," and
  • Potentially year-end completion for the expanded HCC Phase 1 trial.
A question: Will Dr. Rosemurgy be the PI for a pancreas P1 trial?

No comments:

Post a Comment